Eli Lilly, Novartis back a biotech startup boasting 'best of both worlds' protein degraders

Eli Lilly, Novartis back a biotech startup boasting 'best of both worlds' protein degraders

Source: 
Endpoints
snippet: 

Since heading up GlaxoSmithKline’s protein degradation unit in 2012, Ian Churcher has witnessed a rapid explosion of interest in the idea of leveraging the body’s garbage disposal system to eliminate problematic proteins. Huge amounts of money are flowing in from biotech VCs and Big Pharma players, bankrolling a huge volume of projects — some of which have now made it to the clinic.